Names and pronunciation
(des′lor-at′ah-deen) Aerius , Aerius Kids , Allergy Control Clarinex, Clarinex RediTabs
Source page 364
Loading InternPractice…
Individual generic drug information
Extracted information for desloratadine only.
(des′lor-at′ah-deen) Aerius , Aerius Kids , Allergy Control Clarinex, Clarinex RediTabs
Source page 364
Func. class.: Antihistamine, second generation
Source page 364
Chem. class.: Selective histamine (H1)-receptor antagonist
Source page 364
ACTION: Binds to peripheral hista- mine receptors, thus providing antihista- mine action without sedation
Source page 364
USES: Seasonal/perennial allergic rhini- tis, chronic idiopathic urticaria, pruritus
Source page 364
Extracted information for desloratadine only.
CONTRAINDICATIONS: Hyper- sensitivity, infants/neonates Precautions: Pregnancy, breastfeeding, child, asthma, renal/hepatic impairment, phenylketonuria
Source pages 364, 365
SIDE EFFECTS CNS: Sedation (more common with increased doses), headache, psycho- motor hyperactivity, seizures, fatigue, dizziness GI: Hepatitis, nausea, dry mouth MISC: Flulike symptoms, pharyngitis, myalgias
Source page 365
INTERACTIONS Increase: CNS depression (rare)—alco- hol, opiates, sedative/hypnotics, H1 blockers, antipsychotics, tricyclic antide- pressants, anxiolytics Increase: desloratadine—nilotinib, etra- virine
Source page 365
Extracted information for desloratadine only.
DOSAGE AND ROUTES • Adult and child ≥12 yr: PO 5 mg/day • Child 6-11 yr: PO 2.5 mg/day • Child 2-5 yr: PO 1.25 mg/day • Child 6-11 mo: PO 1 mg/day (urti- caria only) Hepatic/renal dose • Adult: PO 5 mg every other day
Source page 365
Available forms: Tablets 5 mg; orally disintegrating tablets 2.5, 5 mg (RediT- abs); oral solution 0.5 mg/mL
Source page 365
Administer: • Without regard to meals • Do not remove RediTabs from blister until ready to use • RediTabs directly on tongue; may take with or without water • Use calibrated device for syrup
Source page 365
Extracted information for desloratadine only.
Assess: • Allergy: hives, rash, rhinitis; monitor respiratory status; stop product 4 days prior to antigen skin test • Pregnancy/breastfeeding: identify whether pregnancy is planned or suspected; use only if benefits outweigh fetal risk; avoid breastfeeding, excretion unknown
Source page 365
Evaluate: • Therapeutic response: absence of running or congested nose, other allergy symptoms
Source page 365
CLINICAL CONSIDERATIONS
Source page 365
Patient and caregiver information: D • To avoid driving, other hazardous ac- tivities if drowsiness occurs; to use cau- tion until product’s effects are known • That product may cause photosensitiv- ity; to use sunscreen or stay out of the sun to prevent burns • Not to exceed max dose, to take with- out regard to meals • To use RediTab by removing from pack and allowing to dissolve on tongue, without regard to water
Source page 365
Extracted information for desloratadine only.
PHARMACOKINETICS Onset antihistamine effect 1 hr, peak 1½ hr, elimination half-life 8½-28 hr, metab- olized in liver to active metabolites, excreted in urine
Source page 365
Filter the extracted dose blocks for this individual drug.
• Adult and child ≥12 yr: PO 5 mg/day
Candidate age grouping · source page 365
• Adult: PO 5 mg every other day
Candidate age grouping · source page 365